Kubota Vision

Kubota Vision is a clinical-stage biotech focused on ophthalmic diseases, advancing a hybrid pipeline of small molecule therapeutics and novel medical devices. Its lead asset is emixustat HCl, in development for Stargardt disease and proliferative diabetic retinopathy, while its device portfolio includes the Kubota Glass for myopia control and remote retinal monitoring systems. The company leverages its position within the Kubota Pharma Group to pursue a dual strategy of treating retinal diseases and managing common refractive errors with high-tech solutions.

Dual-platform focusing on small molecule visual cycle modulators (emixustat HCl) and novel ophthalmic devices including wearable peripheral defocus technology (Kubota Glass) and home-based remote retinal monitoring/OCT systems (eyeMO).

In myopia control, Kubota Glass competes with pharmacological approaches (low-dose atropine) and other optical devices (specialty contact lenses, orthokeratology). In retinal diseases, emixustat faces competition from numerous companies developing gene therapies, anti-VEGF drugs, and other small molecules for conditions like Stargardt and diabetic retinopathy, including large players like Roche, Novartis, and Regeneron.